Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

BioFlyte, a biodefense company set up to commercialize a revolutionary new class of field-based biological threat collection, detection, and identification solutions, announced that it has raised $1. $25 million in new funding This seed stage of the equity financing round was led by the venture capital firm Anzu Partners The funding will accelerate the development of BioFlyte’s field-based mass spectrometer, which enables miniaturized, low-cost and low-power detection and identification of airborne microbes and toxins in real-time.

“BioFlyte focuses on critical infrastructure protection and emergency response,” said Charles Call, PhD, co-founder and Chief Executive Officer of BioFlyte. “BioFlyte is building on more than a decade of critical research and development, including the work of our sister company Zeteo Tech, Inc. , a technology development and innovation engine based in Sykesville, Maryland; “That’s right.

BioFlyte’s first product is a z750 handheld collector designed to supply CBRN Defense Forces and Emergency Response Teams with an advanced, high-performance handheld aerosol sampler. The Z750 handheld collector is designed around the proven dry filter technology that has been used worldwide for decades. The advanced filter design incorporated in the z750 has extensively validated sample extraction protocols and is compatible with PCR, immunoassay and field-based mass-specific instruments, as well as analytical methods associated with laboratory confirmation.

BioFlyteTM z200 is a breakthrough combination collector/detector/identifier system that uses matrix-assisted laser desorption and ionization (MALDI) mass spectrometry to obtain a mass spectrum from the collected aerosol sample. The US Department of Defense has supported the development of z200 mass spectrometer technology in part through the Small Business Innovative Research or SBIR programme.

The company has also announced that Dr. Wayne Bryden, Mr. David Seldin joined the board of directors of the company Dr. Bryden is a co-founder and CEO of Zeteo Tech and previously served as Chief Science Officer of ICx Technologies (acquired by FLIR Systems) and Director of DARPA after many years of research at the John Hopkins University Applied Physics Laboratory.

Oh, Mr. Seldin is the managing partner of Anzu Partners, a venture capital firm that invests in advanced industrial technologies.

“BioFlyte is commercializing some of the much-needed breakthrough technology for the biodefense community,” said Dr. Bryden’s “Z200 provides a presumptive identification in five minutes and can be upgraded quickly and cheaply to detect new or emerging threats. “That’s right.

For more information on BioFlyte and its products, please visit: https://bioflyte Come on,

About BioFlty
BioFlyte is a venture-backed biodefense and microbial identification company that markets a revolutionary new class of field-based biological threat collection, detection and identification solutions. The current focus of the firm’s application is critical infrastructure protection and emergency response For more information on BioFlyte and its technology, please visit: https://bioflyte Come on,

About Partners of Anzu
Anzu Partners is a venture capital and private equity firm that invests in advanced industrial technologies. Anzu teams up with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity and operations. Visit https://anzupartners for more information. Come on, @anzupartner on Twitter

Please note that this piece of work originally appeared in English at As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at

Leave a Reply

Your email address will not be published. Required fields are marked *